Tuesday, November 29, 2005

Merck trial - Dodgeball document

With the third Merck Vioxx trial due to start today Insider thought that you might want to see this for yourself:
Dodgeball

2 comments:

Anonymous said...

Funny part is... Celepfizer is no safer. Pfizer just did a better job cooking the data.

Anonymous said...

I agree with the above, Pfizer did a better job marketing the data. With the recent data, not sure the traditional NSAIDs do not pose a cardiovascular risk.